Using modified Desmopressin for better imaging in Cushing syndrome

Modified Desmopressin (Mdesmo Cold-Kit) for PET Imaging to Localize Adrenocorticotropic Hormone (ACTH) Dependent Cushing Syndrome (CS)

This study is testing a new way to use a modified form of Desmopressin to improve imaging for people with Cushing syndrome, helping doctors better see and understand pituitary tumors before surgery.

Quick facts

• Study type: Observational
• Enrollment: 100 (estimated)
• Ages: 5 Years to 75 Years
• Sex: All
• Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh (other)
• Locations: 1 site (Chandigarh)
• Trial ID: NCT06962202 on ClinicalTrials.gov

What this trial studies

This observational study focuses on improving the diagnosis of Cushing syndrome, particularly distinguishing Cushing disease from ectopic Cushing syndrome. It utilizes a modified form of Desmopressin, radiolabeled with Gallium-68, for enhanced imaging through PET/CT scans. The goal is to provide clearer anatomical and functional information about pituitary tumors, which are often difficult to visualize accurately with current imaging techniques. By preparing a freeze-dried cold-kit for this purpose, the study aims to facilitate better surgical navigation during transsphenoidal surgery for affected patients.

Who should consider this trial

Good fit: Ideal candidates for this study are patients aged 5 to 75 years diagnosed with endogenous Cushing's syndrome.

Not a fit: Patients with exogenous steroid exposure, ongoing pregnancy, or severe comorbid conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to more accurate diagnoses and improved surgical outcomes for patients with Cushing syndrome.

How similar studies have performed: While this approach is innovative, similar imaging techniques have shown promise in enhancing tumor visualization in other conditions, suggesting potential for success.

Eligibility criteria

Inclusion Criteria:

1. Patients diagnosed with endogenous Cushing's syndrome
2. Patients in the age group of 5 to 75 years.
3. Patients willing to give informed consent.

Exclusion Criteria:

1. Patient with exogenous exposure to steroids
2. Ongoing pregnancy
3. Severe comorbid conditions that may interfere with the study.

Where this trial is running

Chandigarh

• Post Graduate Institute of Medical Sciences — Chandigarh, India (RECRUITING)

Study contacts

• Study coordinator: Rama Walia, DM, Endocrinology

Conditions: Cushing Syndrome, ACTH, bilateral inferior petrosal sinus sampling, Corticotropinoma, transsphenoidal surgery, PET/CT